EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates

Jennifer L Fisher, Elizabeth J Wilk, Vishal H Oza, Sam E Gary iD, Timothy C Howton, Victoria L Flanary, Amanda D Clark iD, Anita B Hjelmeland, Brittany N Lasseigne iD

FEBS Open Bio · 2024

DOI: 10.1002/2211-5463.13796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2024. Verfasst von Jennifer L Fisher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell, Developmental and Integrative Biology, Heersink School of Medicine, The University of Alabama at Birmingham, AL, USA. Hauptthemen laut MEDLINE: Drug Repositioning, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHGRI NIH HHS, NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug repurposing is promising because approving a drug for a new indication requires fewer resources than approving a new drug. Signature reversion detects drug perturbations most inversely related to the disease‐associated gene signature to identify drugs that may reverse that signature. We assessed the performance and biological relevance of three approaches for constructing disease‐associated gene signatures (i.e., limma, DESeq2, and MultiPLIER) and prioritized the resulting drug repurposing candidates for four low‐survival human cancers. Our results were enriched for candidates that had been used in clinical trials or performed well in the PRISM drug screen. Additionally, we found that pamidronate and nimodipine, drugs predicted to be efficacious against the brain tumor glioblastoma (GBM), inhibited the growth of a GBM cell line and cells isolated from a patient‐derived xenograft (PDX). Our results demonstrate that by applying multiple disease‐associated gene signature methods, we prioritized several drug repurposing candidates for low‐survival cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningAntineoplastic AgentsHumansAnimalsCell Line, TumorMiceGlioblastomaGene Expression ProfilingXenograft Model Antitumor AssaysGene Expression Regulation, NeoplasticBrain NeoplasmsNeoplasmsTranscriptome

Stichwörter der Autor:innen

cancerdrug repurposinggene signatureglioblastomatranscriptomic signature

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Cell, Developmental and Integrative Biology, Heersink School of Medicine, The University of Alabama at Birmingham, AL, USA.

ORCID-Profile: Sam E Gary, Amanda D Clark, Brittany N Lasseigne

Förderung

  • NHGRI NIH HHS
  • NIH HHS
  • NIGMS NIH HHS
  • NIDDK NIH HHS
  • NIH Office of the Director
  • American Cancer Society
  • National Institute of General Medical Sciences
  • National Human Genome Research Institute

Zitieren

APA

Fisher, J. L., Wilk, E. J., Oza, V. H., Gary, S. E., Howton, T. C., Flanary, V. L., Clark, A. D., Hjelmeland, A. B., & Lasseigne, B. N. (2024). Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13796

Vancouver

Fisher JL, Wilk EJ, Oza VH, Gary SE, Howton TC, Flanary VL, et al. Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates. FEBS Open Bio. 2024. doi:10.1002/2211-5463.13796

BibTeX
@article{Fisher2024,
  author = {Fisher, Jennifer L and Wilk, Elizabeth J and Oza, Vishal H and Gary, Sam E and Howton, Timothy C and Flanary, Victoria L and Clark, Amanda D and Hjelmeland, Anita B and Lasseigne, Brittany N},
  title = {Signature reversion of three disease‐associated gene signatures prioritizes cancer drug repurposing candidates},
  journal = {FEBS Open Bio},
  year = {2024},
  doi = {10.1002/2211-5463.13796}
}
Kostenlos starten →